Sustained Virologic Response
"Sustained Virologic Response" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS.
Descriptor ID |
D000072230
|
MeSH Number(s) |
E01.789.800.570 N04.761.559.590.800.665 N05.715.360.575.575.800.665
|
Concept/Terms |
Sustained Virologic Response- Sustained Virologic Response
- Response, Sustained Virologic
- Sustained Virologic Responses
- Virologic Response, Sustained
- Sustained Viral Suppression
- Suppression, Sustained Viral
- Sustained Viral Suppressions
|
Below are MeSH descriptors whose meaning is more general than "Sustained Virologic Response".
Below are MeSH descriptors whose meaning is more specific than "Sustained Virologic Response".
This graph shows the total number of publications written about "Sustained Virologic Response" by people in this website by year, and whether "Sustained Virologic Response" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2016 | 1 | 0 | 1 |
2017 | 0 | 2 | 2 |
2019 | 1 | 2 | 3 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sustained Virologic Response" by people in Profiles.
-
Schafer JJ, Zimmerman M, Walshe C, Cerankowski J, Shimada A, Keith SW. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide. Obesity (Silver Spring). 2022 Jun; 30(6):1197-1204.
-
Chaganti J, Marripudi K, Staub LP, Rae CD, Gates TM, Moffat KJ, Brew BJ. Imaging correlates of the blood-brain barrier disruption in HIV-associated neurocognitive disorder and therapeutic implications. AIDS. 2019 10 01; 33(12):1843-1852.
-
Murnane PM, Bacchetti P, Currier JS, Brummel S, Okochi H, Phung N, Louie A, Kuncze K, Hoffman RM, Nematadzira T, Soko DK, Owor M, Saidi F, Flynn PM, Fowler MG, Gandhi M. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. AIDS. 2019 08 01; 33(10):1657-1662.
-
Brezzi M, Bertisch B, Roelens M, Moradpour D, Terziroli Beretta-Piccoli B, Semmo N, M?llhaupt B, Semela D, Negro F, Keiser O. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS One. 2019; 14(6):e0218706.
-
Gauthiez E, Habfast-Robertson I, R?eger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, M?llhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud PY. A systematic review and meta-analysis of HCV clearance. Liver Int. 2017 10; 37(10):1431-1445.
-
Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 01; 74(2):180-184.
-
Raffi F, Esser S, Nunnari G, P?rez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016 10; 17 Suppl 5:3-16.